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Background 
Acid suppressive therapy (AST) is used in a variety of indications which range from prevention, i.e. 
stress-ulcer prophylaxis (SUP) in critically ill patients and prevention of gastro-intestinal (GI) ulcers 
associated with non-steroidal anti-inflammatory drug (NSAID) treatment, to treatment, i.e. peptic 
ulcer disease, gastroesophageal reflux disease (GERD), GI bleeding, GI ulcers, dyspepsia, eradication of 
Helicobacter pylori, Zollinger-Ellison syndrome, erosive gastritis and esophagitis. 
In critically ill patients, it has been shown that initiation of SUP in patients with several risk factors, is 
beneficial and prevents fatal bleeding 1. However, in non-critically ill hospitalized patients, data on risk 
stratification and potential efficacy of SUP are scarce 2. Prevention of gastroduodenal lesions related 
to the use of NSAID is only indicated for patients with clearly defined risk factors 3. Guidelines are 
available for treatment of acid related disorders, such as bleeding stomach or duodenal ulcers, 
dyspepsia and GERD 4.  
It has generally been accepted that proton pump inhibitors (PPI) are effective and safe, also when used 
on a chronic and daily basis 5. However, recent reports describing hypomagnesaemia, hypocalcemia, 
osteoporosis, vitamin B12 deficiency and enteric infections (including Clostridium difficile infections) 
were published 6-10. An increase in the risk of postoperative pneumonia was shown when patients were 
treated with PPI for SUP 11. Alzheimer’s disease has been correlated to long-term exposure to PPIs 12. 
Both H2-receptor-antagonists (H2RA) and PPIs have also the potential to be involved in clinically 
relevant drug-drug interactions, at the level of absorption by gastric pH modulation, inhibition of 
CYP450 mediated metabolism and inhibition of transporter-mediated renal excretion 6,8,9. Moreover, 
initiation of AST during hospital stay followed by long-term continuation after discharge was associated 
with an increase in drug costs 1,13,14. 
 
Objectives 
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The primary goal of this observational, retrospective study was to assess the proportion of patients 
with appropriate initiation and continuation at discharge of AST in non-critically ill patients. Secondary 
endpoints were the assessment of the correlation between different patient- and disease-related 
criteria and the appropriateness of initiation of AST and a calculation of costs of AST from the 
healthcare payer perspective. 
 
Methods 
Ethical approval 
This study was approved by the human ethics committee of the University Hospitals of the Catholic 
University of Leuven. 
 
Patient population 
All hospitalized patients discharged from the 1,950-bed University Hospitals Leuven between July 2012 
and July 2013 were included; deceased patients, pediatric patients (younger than 18 years at time of 
discharge), patients admitted to the intensive care unit, patients without startup of AST and patients 
without AST at discharge were excluded (Appendix A). The assessment of appropriateness was 
performed on a random sample of 600 patients, and was carried out by medical record review by six 
trained pharmacy students 15.  
 
Development of a validated screening tool and actual chart review 
To review the medical charts for appropriate startup of AST, a screening tool was developed based on 
existing guidelines. All factors mentioned in Table 1 were considered as arguments confirming 
appropriate initiation and continuation of AST, along with patient- and morbidity related variables. The 
content of the tool was validated by an expert panel of a gastroenterologist, an intensive care physician 
specialized in gastro-enterology and 3 hospital pharmacists. The 3 hospital pharmacists also defined 
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the ‘reference standard’ for further validation of the tool by screening 10 randomly selected medical 
records and discussing to unanimity.  
 
Inter-rater validity of the screening instrument was evaluated by 10 pharmacist-raters (with and 
without clinical experience, with and without expertise in screening medical records) by evaluating the 
10 randomly selected medical records. The results of every rater were compared to the ‘reference 
standard’ and Cohen’s kappa coefficient was calculated. The strength of agreement was set to at least 
0.61, corresponding to ‘substantial inter-rater validity’ as defined by Landis and Koch 16. 
 
The screening tool was used to guide the evaluation of 600 medical files by 6 trained pharmacy 
students under supervision of the principal investigator. 
 
 
Data collection  
All relevant data concerning initiation of AST, including patient demographics, patient’s medical 
history, ambulatory therapy, discharge letter, hospitalization details (hospital ward, diagnosis on 
admission, length of stay), diagnostic tests such as gastroscopy, biopsy results, a selection of 
biochemical parameters (white blood cells (WBC), international normalized ratio (INR), activated 
partial thromboplastin time (aPTT), bilirubin level, aspartate aminotransferase (AST), serum albumin, 
serum creatinine, estimated glomerular filtration rate (eGFR) as assessed by the CKD-EPI (chronic 
kidney disease epidemiology collaboration) formula, relevant concomitant medication and AST details 
(reason for initiation, product, dose and posology during hospitalization and mentioned in the 
discharge letter) were recorded in a database. 
 
Evaluation of appropriateness 
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The initiation of AST was defined as appropriate when: 1) a PPI or a H2RA was prescribed in indications 
as mentioned on the package insert.  2) AST was used in the prevention of ulcers related to 
concomitant NSAID treatment when at least one risk factor, based on Lanza’s guidelines 17, was present  
18, 19. The recommendations of the Belgian Committee for the Reimbursement of Medicines for the use 
of PPI were in agreement with Lanza’s guidelines. 3) The Therapeutic Guidelines on Stress Ulcer 
Prophylaxis (SUP) 2 were followed as Herzig et al. 20 stated that risk factors for nosocomial 
gastrointestinal bleeding in non-critically ill patients were similar to those identified in ICU patients 21-
23. 4) Other factors relating to the development of stress ulcers, discussed in literature, were 
considered as an argument for appropriate initiation of AST in this study. The main factor justifying 
initiation of AST was concomitant use of NSAID and antiplatelet therapy 24.  
 
If at least one of the abovementioned indications (Table 1) was scored as present, initiation of AST was 
considered appropriate. Indications  responsible for at least 10% of appropriate initiation of AST were 
reassessed at the moment of discharge to detect inappropriate continuation of therapy. 
 
 
Economic analysis 
Total cost of AST for the sample was calculated from a healthcare payer perspective and based on the 
Belgian list prices of April 2016. The cost included only the cost of medication; neither labor time, 
infusion fluids and administration sets for IV-administration, nor possible related adverse drug events 
(ADE) are taken into account. 
For each molecule, dose and route of administration, the minimum price, the mean price and the 
maximum price were calculated based on all brands available on the market. The number of 
administered doses was multiplied by each price to calculate the cost. This sensitivity analysis allowed 
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to calculate the interval over which total costs of AST therapy could vary when different brands were 
used. The mean price was used for reporting. 
While for hospitalisation the cost of the effectively administered doses was used, we calculated the 
cost per month of treatment after discharge based on the given posology at discharge. 
Costs for appropriate and non-appropriate startup were reported separately so the savings of 
eliminating inappropriate startup of AST could be calculated.  
 
Statistical analysis 
For data collection Microsoft Excel 2013 and Microsoft Access 2013 were used. Statistical analysis was 
carried out in SPSS version 23. 
We aimed to include 600 patients to guarantee sufficient power. According to Daniels 25 a sample size 
of 384 records was sufficient to guarantee a 95% confidence level and a precision of 5% for the worst 
case in which 50% of patients were appropriately initiated on AST. In case of a proportion of 
appropriateness of 30% 18 a sample size of 559 records represented a confidence level of 99% and a 
precision of 5%.  
 
Chi-square testing was used to assess if the random selection set of 600 patients could be extrapolated 
to the entire patient population fulfilling the inclusion criteria. Chi-square, Student-t or Mann-Whitney 
U-tests were used to compare patients’ demographics in both patients with appropriate versus non-
appropriate initiation of AST. Appropriate and inappropriate startups were compared using univariate 
and multivariate analysis evaluating potential risk factors correlated to inappropriate AST such as age, 
sex, weight, comorbidities, type of ward, and concomitant medication. Logistical regression 
(confidence interval=95%) and Pearson’s and Spearman’s correlations were used as a simple tool to 
analyse the effect of covariates on a binary outcome variable. 
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Results 
Inter-rater validity of the screening instrument 
The mean kappa coefficient was 0.83 (Ppos=0.87, Pneg=0.96), corresponding to almost perfect agreement 
between the results of the raters and the developed reference standard 16 (Appendix B). 
 
Main results 
Six hundred medical records were randomly selected by a computer from a list with patients fulfilling 
the inclusion criteria (n=2,836). Based on Chi2-tests this sample was representative for the entire study 
population in relation to sex (p=0.80), age (p=0.57), length of stay (p=0.28) and admission for surgery 
(p=0.09). Three medical records were removed due to double selection and important missing 
information in the medical records leading to a final sample of 597 patients.   Patient demographics 
are shown in Appendix C. 
In the sample population 186 patients were treated with H2RA, of which 122 appropriate, and 411 
patients were treated with PPI, of which 216 appropriate. Table 1 shows that in  57% of the patients 
(i.c. 338 patients), AST was appropriately initiated. Note that patients could have more than 1 risk 
factor justifying for appropriate therapy and that 76 % of these justifications could be found in six 
indications (each of them responsible for more than 10 %), i.c. 1) treatment of gastroduodenal ulcers 
and prevention of recurrence, 2) GERD, 3) NSAID in older patients, 4) NSAID in combination with 
anticoagulant or antiplatelet therapy, 5) renal failure and 6) concomitant treatment with antiplatelet 
agents.  
When reassessed at moment of discharge, only 40% of the AST was still appropriate for the patient 
(i.c. 237 patients). The main reason of this diminution was the loss of indication due to discontinuation 
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of NSAID, anticoagulants and/or antiplatelet therapy (loss of 173 justifications) and an improved renal 
clearance (loss of 18 justifications). 
Risk factors 
Appendix D presents patient, disease and setting related factors associated with (in)appropriate AST 
initiation.  Main diagnoses were ICD-9 (International Code of Diseases, version 9) coded and clustered 
into groups for further analysis and reporting. Gastrointestinal main diagnoses were correlated with 
more inappropriate startup of AST. Sub-analysis showed that this was mainly related to abdominal 
surgery wards (p=0.044). Admission via the emergency room (ER), skeletal problems and 
cardiovascular diseases were correlated with more appropriate startup of AST. Comorbidities, also 
expressed as grouped ICD-9 codes, related to endocrinology, cardiovascular diseases and esophagitis 
were positively correlated with appropriate AST while non-gastro-intestinal tumors, hematological 
disorders and soft tissue problems are correlated with inappropriate AST. Statistical analysis that 1) 
main diagnosis, cardiovascular therapy, cardiovascular comorbidity and age older than 65 years were 
correlated variables (p=0.000, correlation=0.403); 2) there was a slight correlation between age older 
than 65 years and admission via the ER (p=0.000, correlation=0.149). 
 
Economic results 
The total cost of AST for the sample population (n=597) was €1,869 (i.c. €3.1306 per patient) during 
hospital stay plus €8,503 (i.c. €14.2429 per patient) per month of therapy after discharge. Sensitivity 
analysis showed that the cost for continued therapy was situated between €7,842 and €10,720 (Table 
2). Extrapolation of the result of the cost analysis to the total population fulfilling the inclusion criteria 
during the study period (n=2,836), lead to a total cost of €8,880 during hospitalisation plus €40,391 
per month of continuation after discharge.  Avoiding inappropriate initiation would lead to a saving of 
€3,805 during hospitalisation plus €17,441 per month after discharge. Based on the reassessment of 
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the 6 main indications at the moment of discharge, savings for not continuing inappropriate AST after 
discharge could reach up to €24,246 per month. 
 
Discussion 
Appropriate startup of AST 
In this study we have shown that long-term AST was initiated without an appropriate indication in 43% 
of patients. This number increased to 60% inappropriate continuation of AST when reassessed at 
moment of discharge. To the best of our knowledge, this is the largest study discussing the 
appropriateness of AST initiation during hospitalisation in a non-critically ill patient cohort, using a 
broad variety of international criteria and guidelines and using a validated screening instrument.  
 
Several studies have demonstrated that AST is frequently used inappropriately in non–critically ill 
patients (26.8% up to 71% of AST is inappropriate, depending on the criteria used to justify 
appropriateness) 2.  An overview of the results of some recent studies concerning the appropriateness 
of AST in non-critically ill patients is given in table 3. The number of included patients varies from 67-
545; two studies were limited to the use of intravenous PPI 26, 27; two studies had a focus on SUP rather 
than evaluating all types of AST 19,26,28 and only two studies focused on initiation of therapy 19,29. These 
differences in study population and design made a straightforward comparison between their and our 
results difficult. However, in most studies more than half of the patients received AST without a clearly 
documented appropriate indication. In all studies, the high level of inappropriateness was explained 
by initiation of SUP.  In our opinion, the proportion of patients with inappropriate AST initiation, i.c. 
43%, was a conservative estimation and probably underestimated, as the presence of only one of the 
criteria presented in Table 1 was considered as sufficient for appropriate startup.  
Risk factors 
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Multiple patient-, disease- and setting related factors were found to be associated with appropriate 
startup of AST in univariate analysis. Some of these factors, such as age over 65 years, diagnostic 
testing including endoscopy and renal markers, were part of the criteria justifying appropriate AST 
initiation (Table 1). However, other factors played a role, such as hospital admission via the ER. The 
hypothesis that this was due to the fact that there were more patients over age of 65 entering the 
hospital via the ER was confirmed by the results of the multivariate analysis. The positive correlation 
for cardiovascular main diagnosis and comorbidities with appropriate AST was probably related due to 
the fact that cardiac problems occurred more frequently in elderly. This was confirmed by a 
multivariate analysis showing correlation with age above 65 year. Admission to abdominal surgery and 
oncology wards were significantly correlated with more inappropriate startup. Patients admitted at 
these wards were very frequently treated based on standing orders including AST. The deletion of AST 
from standing orders might lead to a better appropriateness in the future. Admission to the thoracic, 
geriatric and trauma wards were correlated with more appropriate startup, what in our opinion could 
be explained by the use of revised standing orders (without AST), which was part of the tasks of the 
clinical pharmacists at these wards. There were no clear independent patient characteristics identified 
that could predict for inappropriate initiation of AST in a clinical decision support system. 
 
Economics 
As no data on duration of continuation of AST after discharge were available and the data reflected 
only one hospital, the impact on the national budget could only be expressed as an estimated cost per 
month. The reported cost was an underestimate as only the cost of the drug was taken into account. 
The elimination of inappropriate long-term AST could result in a substantial cost saving and a 
supplementary cost avoidance (1, 13, 14) as long-term adverse effects may have been prevented (6-12). 
Limitations 
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The reference standard for validation of the screening tool was based on the results of an experienced 
rater. This could introduce interpretation errors but the kappa coefficients confirmed the quality of 
the reference standard and the reliability of the raters.  
Results were based on the content of the medical records and thus the number of appropriate startups 
could be underestimated due to missing relevant information. However, as the screening tool included 
simple and standard parameters and all available data sources were combined, the risk for missing 
data was not expected to be high. This was reflected in the benchmark with other studies. 
This study excluded pediatric and critically ill patients, approximately 22% of the hospitalized 
population. For pediatric patients the dosing regimen could not be linked to the dispensing data as 
they used merely compounded liquid medication. Appropriateness of AST in critically ill patients was 
already extensively described in literature. The study focused on appropriateness of startup of long-
term AST and therefore excluded patients already on AST when admitted and patient discharged 
without continuation of AST. 
Possible savings from discontinuing inappropriate AST in the hospital were underestimated because 
only costs of AST medication were included, excluding e.g. nursing time, infusion bag and line, costs of 
treating ADEs. The labor cost for administration of AST was only a fraction of the time spent by 
healthcare professionals and therefore of little impact on the total cost. Also, AST could become 
inappropriate at time of discharge which resulted in an extra saving if AST was stopped at that moment. 
As AST was seen as effective and generally safe there were no data to calculate the cost of an ADE. 
The findings could not be extrapolated to Belgium as the University Hospitals Leuven might not be 
representative for non-teaching hospitals. The same questionnaire should be repeated in other 
hospitals in order to calculate their rate of appropriate therapy and the possible cost savings. 
 
Conclusion 
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We found that 43% of initiation of long-term AST in the hospital was inappropriate. Although the 
financial savings to be gained from avoiding it were low during hospitalisation the potential savings 
after discharge could be substantial from a healthcare payer perspective.  No clear independent 
patient characteristics that could predict for inappropriate initiation of AST in a clinical decision 
support system were identified. We have seen a correlation between inappropriate initiation and 
medical disciplines using standing orders that include AST. 
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